临床与实验病理学杂志2024，Vol.40Issue(1)：29-34,6.DOI:10.13315/j.cnki.cjcep.2024.01.008
原发性CD5+弥漫大B细胞淋巴瘤临床病理及预后的差异分析
Clinical pathology and prognostic differences of primary CD5+diffuse large B cell lymphoma
谢嘉玲 1施晴 2鲍其远 3董磊1
作者信息
- 1. 上海交通大学医学院附属瑞金医院病理科,上海 200020
- 2. 上海交通大学医学院附属瑞金医院血液科,上海 200020
- 3. 上海交通大学医学院附属瑞金医院骨科,上海 200020
- 折叠
摘要
Abstract
Purpose To explore the clinicopathological features and molecular characteristics of primary CD5+diffuse large B cell lymphoma(DLBCL).Methods Immunohisto-chemistry and next-generation sequencing(NGS)were used to compare the pathological features,immunophenotypes,and mo-lecular characteristics between primary CD5+DLBCL and CD5-DLBCL,and to analyze their relationship with prognosis and clinical characteristics of patients.Results Among 311 DLBCL patients,there were 46 cases(14.7％)of CD5+DLBCL.There were no statistically significant differences in patient gen-der,clinical staging,international prognostic index between CD5+DLBCL and CD5-DLBCL,and between CD5+DLBCL with and without MYD88 L265P mutation(P＞0.05).Immuno-phenotypically,the overexpression of BCL2(69.5％vs 49.4％,P=0.003)and the co-expression of BCL2 and C-MYC(26％vs 14％,P=0.04)were higher in the CD5+DLBCL group than those in the CD5-DLBCL group;the expression of C-MYC(53％vs 20％),BCL6(93.3％vs 61.3％),Ki67(93.3％vs 64.5％),and co-expression(46.7％vs 20.8％)were higher in the CD5+with MYD88 L265P mutation group than those in the CD5+without MYD88 L265P mutation group(P＜0.05).Survival analysis showed that the disease progres-sion-free survival time of patients in the CD5+DLBCL group tended to be shorter than that of patients in the CD5-DLBCL group(P=0.09).Furthermore,the disease progression-free survival time of patients in the CD5+without MYD88 L265P mutation group was significantly longer than that of patients in the CD5+with MYD88 L265P mutation group(P=0.04).NGS detection found differences in the distribution of accompan-ying mutated genes between CD5+DLBCL and CD5-DLBCL groups.ConclusionCD5 expression and CD5+with MYD88 L265P mutation may be potential indicators of poor prognosis in DLBCL patients.关键词
原发性弥漫大B细胞淋巴瘤/免疫组织化学/CD5/MYD88 L265PKey words
primary diffuse large B cell lymphoma/immumo-histochemisty/CD5/MYD88 L265P分类
医药卫生引用本文复制引用
谢嘉玲,施晴,鲍其远,董磊..原发性CD5+弥漫大B细胞淋巴瘤临床病理及预后的差异分析[J].临床与实验病理学杂志,2024,40(1):29-34,6.
